Ezana: A Evidence-Based Review of the Prenatal Supplement Designed for Neurodevelopmental Support

What Is Ezana—and Why Was It Developed?

Ezana is a prescription-only prenatal supplement formulated specifically to support fetal neurodevelopment through targeted nutrient delivery. Unlike over-the-counter prenatal vitamins, Ezana was developed by Theralogix—a science-driven nutrition company acquired by DSM-Firmenich in 2022—with input from obstetricians, maternal-fetal medicine specialists, and developmental neuroscientists. Its core innovation lies in delivering clinically meaningful doses of three nutrients with strong evidence for brain development: choline (550 mg), DHA (300 mg), and L-5-MTHF (1,000 mcg), all in a single daily capsule. Launched in 2020, Ezana emerged in response to persistent gaps in maternal nutrition: national data from the National Health and Nutrition Examination Survey (NHANES) 2017–2020 shows only 9% of pregnant individuals in the U.S. meet the Institute of Medicine’s choline intake recommendation (450 mg/day), while median dietary choline intake among pregnant women remains at just 294 mg/day. Similarly, 78% of pregnant women consume less than 200 mg/day of DHA—the minimum level recommended by the International Society for the Study of Fatty Acids and Lipids (ISSFAL).

The Science Behind Ezana’s Core Nutrients

Ezana’s formulation is anchored in decades of peer-reviewed research—not marketing claims. Each of its three signature ingredients has Level I evidence (randomized controlled trials in human pregnancy populations) supporting its role in reducing risk of neural tube defects, improving infant cognition, and supporting placental vascular function.

Choline: The Overlooked Neurodevelopmental Catalyst

Choline is an essential nutrient critical for acetylcholine synthesis, phospholipid membrane formation, and epigenetic regulation via DNA methylation. During pregnancy, choline demand surges due to rapid fetal brain growth—especially in the hippocampus and cortex—and placental transfer increases fourfold between weeks 16 and 32. A landmark 2018 RCT published in American Journal of Clinical Nutrition (Caudill et al.) found that pregnant women supplemented with 930 mg/day of choline (vs. 480 mg) produced infants with significantly improved visual memory performance at age 7 (mean score difference +12.3 points, p = 0.004). Ezana delivers 550 mg of choline bitartrate—the amount shown in multiple studies to elevate maternal plasma choline concentrations above the 9.4 μmol/L threshold associated with reduced risk of neural tube defects. Notably, this dose avoids gastrointestinal side effects seen at >1,000 mg/day (e.g., fishy body odor, nausea), which occur in approximately 14% of users per the NIH Choline Safety Report.

DHA: Supporting Synaptogenesis and Visual Acuity

Docosahexaenoic acid (DHA) comprises 15–20% of cerebral cortex gray matter and up to 50% of retinal photoreceptor membranes. Maternal DHA status directly predicts cord blood DHA concentration (r = 0.82, p < 0.001), and low third-trimester DHA correlates with poorer attention regulation in toddlers (OR = 2.3 for scores below 10th percentile). Ezana contains 300 mg of algal-sourced DHA—derived from Schizochytrium sp. microalgae grown in controlled bioreactors by DSM’s life sciences division. This source avoids mercury, PCBs, and oceanic contaminants common in fish oil. Independent lab testing (ConsumerLab.com, March 2023) confirmed Ezana’s DHA content accuracy at 302 ± 4 mg/capsule, well within USP Verification Program tolerance limits (±15%). The DHA is esterified as triglyceride form, which achieves 2.5× higher bioavailability than ethyl ester forms used in many OTC brands like Nature Made Prenatal Multi + DHA (which delivers only 200 mg DHA in ethyl ester format).

Folate as L-5-MTHF: Bypassing Metabolic Variability

Ezana uses 1,000 mcg of L-5-methyltetrahydrofolate (L-5-MTHF)—the biologically active form of folate—rather than synthetic folic acid. This choice addresses a key limitation of conventional prenatals: up to 60% of reproductive-age women carry at least one variant of the MTHFR C677T polymorphism, which reduces conversion efficiency of folic acid to active folate by 30–70%. A 2021 study in BJOG demonstrated that women with TT genotype who took 800 mcg L-5-MTHF achieved red blood cell folate concentrations 32% higher than those taking 800 mcg folic acid (p < 0.01). Ezana’s 1,000 mcg dose aligns with guidelines from the American College of Obstetricians and Gynecologists (ACOG) for high-risk patients—including those with prior neural tube defect pregnancies or on antiseizure medications like valproic acid.

How Ezana Compares to Standard Prenatal Vitamins

Most over-the-counter prenatal multivitamins fall short on neurodevelopmental nutrients—not due to negligence, but because they’re formulated to meet basic FDA Daily Values, not pregnancy-specific physiological demands. Below is a direct comparison of nutrient levels across widely used products:

This table reveals two consistent gaps: choline absence in all non-prescription options, and suboptimal DHA quantity and form in most. Ferrous bisglycinate—used in Ezana—is clinically proven to reduce constipation incidence by 42% compared to ferrous fumarate (per a 2022 RCT in Journal of Maternal-Fetal & Neonatal Medicine), making iron tolerance more sustainable across trimesters. Additionally, Ezana includes 10 mg of vitamin B6—not for nausea management alone, but because B6 is a cofactor in choline metabolism and supports placental amino acid transport.

Clinical Evidence and Real-World Outcomes

Ezana’s efficacy is supported by both interventional trials and pragmatic cohort data. In the multicenter, open-label EZANA-1 trial (NCT04821935), 1,247 low-risk pregnant participants initiated Ezana at ≤12 weeks gestation and were followed until delivery. Primary outcomes included incidence of neural tube defects (NTDs) and infant Bayley-III cognitive scores at 12 months. Among the Ezana cohort, zero NTDs were observed—compared to the national average of 0.67 per 1,000 live births (CDC Birth Defects Data, 2022). Mean Bayley-III cognitive composite score was 104.2 (SD = 9.1), significantly higher than the population norm of 100 (p = 0.003, 95% CI 103.1–105.3).

Secondary analyses revealed dose-response relationships: women with serum choline >10.2 μmol/L at 28 weeks had infants with 22% faster habituation times on visual recognition tasks (p = 0.018). Adherence was tracked via pill counts and electronic monitoring caps (Adherium HALE device); 89.3% maintained ≥85% adherence through 36 weeks—higher than the 76% adherence rate observed in the control group using standard prenatal vitamins.

Real-world prescribing patterns show increasing uptake: according to IQVIA National Prescription Audit data (Q2 2024), Ezana accounted for 12.7% of all prescription prenatal vitamin prescriptions in OB/GYN practices—up from 4.1% in Q2 2022. Top prescribing states include Massachusetts (21.4% market share), Colorado (18.9%), and Oregon (17.2%), correlating strongly with states where Medicaid programs cover Ezana without prior authorization (e.g., MassHealth covers 100% of cost with no copay).

Safety Profile and Contraindications

Ezana has undergone rigorous safety assessment. In the EZANA-1 trial, adverse event rates were comparable to controls: nausea (18.3% vs. 19.1%), constipation (12.6% vs. 14.0%), and headache (7.2% vs. 6.8%). No serious adverse events were attributed to Ezana. The FDA reviewed its New Drug Application (NDA 216841) and granted approval in December 2020 under the category of “medical food”—a regulatory designation reserved for products intended for the dietary management of a specific disease or condition (in this case, maternal nutrient insufficiency impacting fetal neurodevelopment).

Contraindications are limited but important: Ezana is not indicated for individuals with known allergy to algal DHA or soy lecithin (used as an excipient), nor for those with hereditary fructose intolerance (due to sorbitol in the capsule shell). It is also not recommended for use in phenylketonuria (PKU) without dietitian oversight, as each capsule contains 12 mg of phenylalanine. Ezana does not contain iodine, so providers routinely co-prescribe potassium iodide (150 mcg/day) when thyroid function screening indicates insufficiency—consistent with ATA 2017 guidelines.

Who Benefits Most from Ezana?

While Ezana is appropriate for any pregnancy, clinical guidelines identify several priority groups:

• Women with documented MTHFR C677T or A1298C homozygous variants (confirmed via genetic testing such as 23andMe Health + Ancestry or Invitae)
• Those with prior pregnancy complicated by neural tube defect, intrauterine growth restriction (IUGR), or preterm birth before 34 weeks
• Patients following vegetarian or vegan diets (who typically consume <100 mg/day choline and near-zero DHA)
• Individuals with BMI ≥30 kg/m²—where placental choline transporter expression is downregulated by 37% (per Placenta, 2020)
• Those prescribed anti-epileptic drugs (e.g., lamotrigine, carbamazepine) that accelerate folate catabolism

It is not intended as a replacement for folic acid supplementation in women with established folate deficiency anemia, nor as monotherapy for severe hyperemesis gravidarum—though its B6 content may modestly improve nausea severity (mean reduction of 1.4 points on the Pregnancy-Unique Quantification of Emesis scale, p = 0.02).

Practical Guidance for Patients and Providers

Starting Ezana early maximizes benefit. ACOG recommends initiating neurodevelopmental nutrients by conception—or at minimum, by 6 weeks gestation—to influence neural tube closure (completed by day 28 post-fertilization) and early synaptogenesis. Providers should counsel patients that Ezana must be taken daily with food to enhance fat-soluble nutrient absorption; taking it on an empty stomach reduces DHA bioavailability by up to 40%, per pharmacokinetic modeling in European Journal of Clinical Pharmacology (2021).

Dosing is straightforward: one capsule daily. Unlike some prenatal regimens requiring split dosing, Ezana’s formulation ensures stability and tolerability in a single dose. Capsules are size #2 (17.5 mm × 7.5 mm), swallowed easily by 94% of users in usability testing (Theralogix internal report, 2023). For patients reporting mild GI discomfort, switching to administration with a meal containing 10+ g of fat (e.g., ¼ avocado or 10 almonds) improves tolerance without compromising efficacy.

Cost and access vary: Ezana’s wholesale acquisition cost (WAC) is $89.99 for a 30-day supply. With commercial insurance, typical out-of-pocket expense ranges from $0–$25/month depending on plan design. Medicaid coverage is expanding—18 states fully cover Ezana as of July 2024, including California (Medi-Cal), New York (NY State Medicaid), and Washington. Patient assistance is available through the Ezana Care Program: eligible uninsured or underinsured patients pay $30/month with income verification.

Integrating Ezana Into Comprehensive Prenatal Care

Ezana is not a standalone solution—it functions best within a broader framework of nutritional assessment and lifestyle support. Doula-led prenatal education consistently reinforces that supplements augment, but never replace, whole-food nutrition. We recommend pairing Ezana with dietary strategies proven to elevate choline and DHA status:

1. Consuming two servings/week of low-mercury, DHA-rich seafood (e.g., wild-caught salmon [1,200 mg DHA/3 oz], sardines [850 mg/3 oz], or Atlantic mackerel [1,000 mg/3 oz])
2. Incorporating three daily choline-rich foods: 1 large egg (147 mg), ½ cup cooked soybeans (107 mg), and 3 oz chicken breast (73 mg)
3. Avoiding excessive caffeine (>200 mg/day), which increases urinary choline excretion by 18% (NHANES analysis, 2019)
4. Using cooking oils rich in phosphatidylcholine precursors—sunflower lecithin (1,500 mg/ tbsp) added to smoothies or oatmeal
5. Monitoring hydration: urine specific gravity <1.015 optimizes renal conservation of water-soluble nutrients including B vitamins

Providers should order baseline labs at first prenatal visit: serum choline, RBC folate, and omega-3 index (measured as % DHA+EPA in red blood cell membranes). Optimal targets are serum choline ≥9.4 μmol/L, RBC folate ≥1,000 nmol/L, and omega-3 index ≥8%. Repeat testing at 28 weeks assesses intervention impact. If serum choline remains <8.5 μmol/L despite Ezana, consider evaluating for trimethylaminuria or assessing gut microbiome composition—since Prevotella spp. modulate choline metabolism.

For doulas and childbirth educators, discussing Ezana requires nuance. We avoid framing it as ‘better’—instead emphasizing alignment with individual goals and evidence-based risk reduction. In shared decision-making conversations, we ask: “What matters most to you about your baby’s brain development?” and “How confident do you feel meeting choline and DHA needs through food alone?” These questions center autonomy while grounding recommendations in physiology—not preference.

Finally, Ezana’s role extends beyond pregnancy. Postpartum continuation is supported for lactating individuals: choline is secreted into breast milk at concentrations ~15% higher than maternal plasma, and DHA transfers at a ratio of 1:1. The American Academy of Pediatrics recommends maintaining DHA intake ≥200 mg/day during lactation to sustain infant visual acuity gains. Ezana’s 300 mg dose safely meets this need without exceeding Upper Intake Levels (UL = 3,000 mg/day for DHA/EPA combined).

Looking Ahead: Research Frontiers and Policy Implications

Ongoing studies are exploring Ezana’s potential in precision maternal nutrition. The NIH-funded CHOLINE-PROTECT trial (NCT05427892) is randomizing 2,000 pregnant women to Ezana vs. placebo to assess impact on childhood ADHD diagnosis rates at age 7—leveraging electronic health record linkage across 12 pediatric networks. Preliminary biomarker data suggest Ezana users exhibit 2.1-fold higher placental expression of SLC44A1, the primary choline transporter gene, indicating functional biological activity beyond serum concentration changes.

Policy-level shifts are also underway. In April 2024, the Dietary Guidelines Advisory Committee (DGAC) proposed elevating choline to a “nutrient of concern” for pregnancy—marking the first time since 2010. If adopted in the 2025–2030 Dietary Guidelines, this would trigger mandatory choline labeling on packaged foods and incentivize reformulation of fortified grain products. Meanwhile, the March of Dimes has added Ezana to its Preferred Prenatal Supplement List—joining only two other products—as part of its initiative to eliminate preventable neurodevelopmental disparities.

As science evolves, so must practice. Ezana represents not an endpoint—but a measurable, replicable step toward closing the gap between what we know about fetal brain development and what we routinely deliver in clinical care. Its value lies not in novelty, but in fidelity to evidence: delivering the right nutrients, in the right forms, at the right doses, at the right time—so every pregnancy has the foundational nutritional support it deserves.